Radiopharm Theranostics (RADX) wins approval to speed RAD 202 trial

Rhea-AI Filing Summary

Radiopharm Theranostics Limited filed a Form 6-K as a foreign private issuer to furnish a public notice previously released on the Australian Securities Exchange. The attached exhibit is an announcement dated October 1, 2025 titled “Radiopharm received approval for RAD 202 trial acceleration.” This means the company has received approval related to speeding up its RAD 202 trial and is sharing that information with U.S. investors. The Form 6-K states that this report, including the exhibit, is not deemed “filed” under the U.S. securities laws and will only be incorporated into other securities filings if later specifically referenced.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on October 1, 2025 titled:

-   “Radiopharm received approval for RAD 202 trial acceleration”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Radiopharm received approval for RAD 202 trial acceleration

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: October 1, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3

FAQ

What did Radiopharm Theranostics (RADX) disclose in this Form 6-K?

Radiopharm Theranostics furnished a Form 6-K to provide U.S. investors with a copy of an Australian Securities Exchange announcement titled “Radiopharm received approval for RAD 202 trial acceleration.”

What is the key announcement attached to Radiopharm Theranostics' Form 6-K?

The key announcement, filed as Exhibit 99.1, is titled “Radiopharm received approval for RAD 202 trial acceleration.” It reports that the company has received approval related to accelerating its RAD 202 trial.

When was the ASX announcement about RAD 202 trial acceleration published?

The public notice regarding approval for RAD 202 trial acceleration was published on the Australian Securities Exchange on October 1, 2025.

Does this Radiopharm Theranostics Form 6-K count as a filed document under the Exchange Act?

No. The Form 6-K states that this report, including the exhibit, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.

Will the RAD 202 trial acceleration announcement be automatically incorporated into other Radiopharm Theranostics SEC filings?

No. The report explains that it will not be incorporated by reference into any Securities Act filing unless a future filing expressly incorporates it by specific reference.

What exhibit is included with Radiopharm Theranostics' October 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, titled “Radiopharm received approval for RAD 202 trial acceleration.”